ArticlePLoS pathogens2017
What matters in chronic Burkholderia cenocepacia infection in cystic fibrosis: Insights from comparative genomics.
Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Genomic Insights into a New Burkholderia cenocepacia Sequence Type Linked to Cepacia Syndrome in Cystic Fibrosis.Current microbiology · 2026Article
- Real-time investigation of a Burkholderia cenocepacia bacteraemia outbreak in a Vietnamese intensive care unit.The Journal of hospital infection · 2025Article
- Regulatory roles of non-coding RNAs in programmed cell death pathways and drug resistance in gastrointestinal stromal tumors.Clinical and experimental medicine · 2025Review
- Quorum sensing and DNA methylation play active roles in clinicalJournal of bacteriology · 2025Article
- Antibacterial Activity of a Natural Clay Mineral againstMicroorganisms · 2023Article
- Genomic features, antimicrobial susceptibility, and epidemiological insights intoFrontiers in cellular and infection microbiology · 2023Article
- Adaptation and Evolution of Pathogens in the Cystic Fibrosis Lung.Journal of the Pediatric Infectious Diseases Society · 2022Review
- Bacterial evolution during human infection: Adapt and live or adapt and die.PLoS pathogens · 2021Review
- In vivo evolution of an emerging zoonotic bacterial pathogen in an immunocompromised human host.Nature communications · 2021Article
- Pan-Genome Analysis Reveals Host-Specific Functional Divergences inMicroorganisms · 2021Article
- Genomics of an endemic cystic fibrosis Burkholderia multivorans strain reveals low within-patient evolution but high between-patient diversity.PLoS pathogens · 2021Article
- Bacterial defenses against a natural antibiotic promote collateral resilience to clinical antibiotics.PLoS biology · 2021Article
- One gene, multiple ecological strategies: A biofilm regulator is a capacitor for sustainable diversity.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Impact of insertion sequences on convergent evolution of Shigella species.PLoS genetics · 2020Article
- Comparative Evolutionary Patterns ofFrontiers in microbiology · 2020Article
- Variation of Burkholderia cenocepacia cell wall morphology and mechanical properties during cystic fibrosis lung infection, assessed by atomic force microscopy.Scientific reports · 2019Article
- The Effect of 2-Thiocyanatopyridine Derivative 11026103 onAntibiotics (Basel, Switzerland) · 2019Article
- Article
- A genome-wide association analysis reveals a potential role for recombination in the evolution of antimicrobial resistance in Burkholderia multivorans.PLoS pathogens · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkholderia cenocepacia causes severe pulmonary infections in cystic fibrosis (CF) patients. Since the bacterium is virtually untreatable by antibiotics, chronic infections persist for years and might develop into fatal septic pneumonia (cepacia syndrome, CS). To devise new strategies to combat chronic B. cenocepacia infections, it is essential to obtain comprehensive knowledge about their pathogenesis. We conducted a comparative genomic analysis of 32 Czech isolates of epidemic clone B. cenocepacia ST32 isolated from various stages of chronic infection in 8 CF patients. High numbers of large-scale deletions were found to occur during chronic infection, affecting preferentially genomic islands and nonessential replicons. Recombination between insertion sequences (IS) was inferred as the mechanism behind deletion formation; the most numerous IS group was specific for the ST32 clone and has undergone transposition burst since its divergence. Genes functionally related to transition metal metabolism were identified as hotspots for deletions and IS insertions. This functional category was also represented among genes where nonsynonymous point mutations and indels occurred parallelly among patients. Another category exhibiting parallel mutations was oxidative stress protection; mutations in catalase KatG resulted in impaired detoxification of hydrogen peroxide. Deep sequencing revealed substantial polymorphism in genes of both categories within the sputum B. cenocepacia ST32 populations, indicating extensive adaptive evolution. Neither oxidative stress response nor transition metal metabolism genes were previously reported to undergo parallel evolution during chronic CF infection. Mutations in katG and copper metabolism genes were overrepresented in patients where chronic infection developed into CS. Among professional phagocytes, macrophages use both hydrogen peroxide and copper for their bactericidal activity; our results thus tentatively point to macrophages as suspects in pathogenesis towards the fatal CS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.